Eisai and Nichi-Iko extend partnership to target China 30-Sep-2019 By Ben Hargreaves The Japanese drugmakers will collaborate to sell generic products in China, with the aim of launching ‘one to two products’ every year.
FDA approves Omega Laboratories for manufacturing 10-Sep-2019 By Vassia Barba Sagent announces the approval of its subsidiary’s facility in Canada to manufacture small molecule drug products for the US market.
NEWS IN BRIEF Sagent acquires US facility with an eye on future biosimilar products 12-Mar-2019 By Staff reporter Sagent purchases Xellia’s FDA-approved site in North Carolina, which has capabilities to manufacture both small molecule and biologic products.